Christopher Bryant
Plus aucun poste en cours
Profil
Christopher Bryant served as the Chief Scientific Officer & Executive VP at APP Pharmaceuticals, Inc. He then held the same position at Fresenius Kabi Pharmaceuticals Holding LLC from 2009 to 2013.
He also served as the Chief Operating Officer & Executive Vice President at ProMetic BioTherapeutics, Inc. Dr. Bryant earned a doctorate degree from the University of California San Diego.
Anciens postes connus de Christopher Bryant
| Sociétés | Poste | Fin |
|---|---|---|
Fresenius Kabi Pharmaceuticals Holding LLC
 Fresenius Kabi Pharmaceuticals Holding LLC Pharmaceuticals: MajorHealth Technology Fresenius Kabi Pharmaceuticals Holding LLC is a pharmaceutical company, which engages in the development, manufacturing, and marketing of injectable pharmaceutical products. It primarily focuses on the injectable oncology, anti-infective, anesthetic/analgesic, and critical care markets. The firm manufactures products in each of the three basic forms, which include liquid, powder, and lyophilized or freeze-dried. Its products are generally used in hospitals, long-term care facilities, alternate care sites and clinics. The company was founded on July 2, 2008 and is headquartered in Wilmington, DE. | Directeur Technique/Scientifique/R&D | 01/12/2013 |
APP Pharmaceuticals, Inc.
 APP Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology APP Pharmaceuticals, Inc. develops, manufactures and markets injectable pharmaceutical products with a primary focus on the oncology, anti-infective, anesthetic/analgesic and critical care markets. It offers one of the most comprehensive product portfolios used in hospitals, long-term care facilities, alternate care sites and clinics within North America and manufactures a comprehensive range of dosage formulations. The company is headquartered in Los Angeles, CA. | Directeur Technique/Scientifique/R&D | - |
ProMetic BioTherapeutics, Inc.
 ProMetic BioTherapeutics, Inc. BiotechnologyHealth Technology Part of KEDRION HOLDING S.P.A., ProMetic BioTherapeutics, Inc. is a company that manufactures plasma protein fractionation products. The company is based in Rockville, MD. ProMetic BioTherapeutics was acquired by Kedrion Biopharma, Inc. on October 18, 2021. | Directeur des opérations | - |
Formation de Christopher Bryant
| University of California San Diego | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
APP Pharmaceuticals, Inc.
APP Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology APP Pharmaceuticals, Inc. develops, manufactures and markets injectable pharmaceutical products with a primary focus on the oncology, anti-infective, anesthetic/analgesic and critical care markets. It offers one of the most comprehensive product portfolios used in hospitals, long-term care facilities, alternate care sites and clinics within North America and manufactures a comprehensive range of dosage formulations. The company is headquartered in Los Angeles, CA. | Health Technology |
Fresenius Kabi Pharmaceuticals Holding LLC
Fresenius Kabi Pharmaceuticals Holding LLC Pharmaceuticals: MajorHealth Technology Fresenius Kabi Pharmaceuticals Holding LLC is a pharmaceutical company, which engages in the development, manufacturing, and marketing of injectable pharmaceutical products. It primarily focuses on the injectable oncology, anti-infective, anesthetic/analgesic, and critical care markets. The firm manufactures products in each of the three basic forms, which include liquid, powder, and lyophilized or freeze-dried. Its products are generally used in hospitals, long-term care facilities, alternate care sites and clinics. The company was founded on July 2, 2008 and is headquartered in Wilmington, DE. | Health Technology |
ProMetic BioTherapeutics, Inc.
ProMetic BioTherapeutics, Inc. BiotechnologyHealth Technology Part of KEDRION HOLDING S.P.A., ProMetic BioTherapeutics, Inc. is a company that manufactures plasma protein fractionation products. The company is based in Rockville, MD. ProMetic BioTherapeutics was acquired by Kedrion Biopharma, Inc. on October 18, 2021. | Health Technology |
